Hanns Möhler – författare

This volume is the third edition of a monograph series that was first published in 1983. The demand for this work is a testament to the impact of studies on -aminobutyric acid (GABA) receptors on the basic understanding of synaptic transmission and on defining the clinical importance of the neurotransmitter system. Chronicled in The GABA Receptors, Third Edition, are the advances made in understanding the molecular and pharmacological properties of GABA A and GABA receptors since the topic was last reviewed in 1996. Particular B emphasis is placed on describing the assembly, structure, and function of GABA B sites, the first heterodimeric G protein-coupled receptors identified in vivo. In addition, there are reports dealing with the subunit composition, trafficking, and pharmacological selectivity of GABA receptors. Aside from providing A insights into the fundamental properties of ligand-gated ion channels and second messenger systems, the findings detailed in this work point the way for developing novel therapeutics capable of more selectively manipulating these transmitter sites.

This volume is the third edition of a monograph series that was first published in 1983. The demand for this work is a testament to the impact of studies on -aminobutyric acid (GABA) receptors on the basic understanding of synaptic transmission and on defining the clinical importance of the neurotransmitter system. Chronicled in The GABA Receptors, Third Edition, are the advances made in understanding the molecular and pharmacological properties of GABA A and GABA receptors since the topic was last reviewed in 1996. Particular B emphasis is placed on describing the assembly, structure, and function of GABA B sites, the first heterodimeric G protein-coupled receptors identified in vivo. In addition, there are reports dealing with the subunit composition, trafficking, and pharmacological selectivity of GABA receptors. Aside from providing A insights into the fundamental properties of ligand-gated ion channels and second messenger systems, the findings detailed in this work point the way for developing novel therapeutics capable of more selectively manipulating these transmitter sites.

GABA (gamma-aminobutyric acid) is the main neurotransmitter regulating sleep. The majority of drugs presently in use for the treatment of sleep disorders act by enhancing GABAergic neuronal inhibition. The GABA system is, therefore, of prime clinical relevance for the therapy of insomnia. The focus of this volume is on the neuropsychopharmacology and the clinical impact of the GABA system in regulating sleep and wakefulness. It presents molecular, neuropharmacological, systems-biological and clinical approaches to the understanding of the mechanism of action of GABA and GABAergic drugs. It also explores the role of GABA in the basic drives that affect sleep, and the influences that adapt sleep and wakefulness to external events.

GABA (gamma-aminobutyric acid) is the main neurotransmitter regulating sleep. The majority of drugs presently in use for the treatment of sleep disorders act by enhancing GABAergic neuronal inhibition. The GABA system is, therefore, of prime clinical relevance for the therapy of insomnia. The focus of this volume is on the neuropsychopharmacology and the clinical impact of the GABA system in regulating sleep and wakefulness. It presents molecular, neuropharmacological, systems-biological and clinical approaches to the understanding of the mechanism of action of GABA and GABAergic drugs. It also explores the role of GABA in the basic drives that affect sleep, and the influences that adapt sleep and wakefulness to external events.